Clinical Trial: Morbidity and Mortality Follow Up for the Scleroderma Lung Study

Study Status: Completed
Recruit Status: Completed
Study Type: Observational




Official Title: Morbidity and Mortality Follow Up of Participants of the Scleroderma Lung Study 1

Brief Summary: The primary intent of this study is to add to the body of knowledge on scleroderma patients with interstitial lung disease. While lung disease is recognized as the leading cause of death amongst patients with scleroderma, there is not a large body of literature describing the long-term morbidity and mortality rate of these scleroderma patients. For this reason, the investigators are following participants of the Scleroderma Lung Study (NCT00004563) after their participation in that study was concluded. In addition, the investigators will assess if the subjects who received one year of oral cyclophosphamide in the Scleroderma Lung Study experienced progression of their scleroderma-related lung disease following the end of the study.